A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL

被引：0
|
作者：
Silva Miguel, L. [1 ]
Pinheiro, B. [1 ]
Lopes, R. [1 ]
Revil, C. [2 ]
Monteiro, I [3 ]
Borges, M. [4 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, Lisbon 11, Portugal
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Roche Farmaceut Quim Lda, Amadora, Portugal
[4] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB51
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [21] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [22] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [23] Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Hu, Shanshan
    Wu, Yilai
    Luan, Jiajie
    Wang, Shuowen
    Fan, Guorong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 17933 - 17942
  • [24] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [25] Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada
    Younis, T.
    Lee, A.
    Coombes, M. E.
    Bouganim, N.
    Becker, D.
    Revil, C.
    Jhuti, G. S.
    CURRENT ONCOLOGY, 2020, 27 (06) : E578 - E589
  • [26] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [27] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [28] COST-UTILITY ANALYSIS OF ADJUVANT TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB IN PATIENTS WITH HER2+EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT THERAPY IN SPAIN
    Colomer, R.
    Arroyo, I
    Costa-Samarra, J.
    Gallego, T.
    VALUE IN HEALTH, 2020, 23 : S442 - S442
  • [29] Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumabfor the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran
    Hemati, Homa
    Nosrati, Marzieh
    Seyedifar, Meysam
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01):
  • [30] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    CANCER, 2007, 110 (03) : 489 - 498
12345